Liver injury caused by antiviral agents for COVID-19 / 中华临床感染病杂志
Chinese Journal of Clinical Infectious Diseases
;
(6): 102-108, 2020.
Artículo
en Chino
| WPRIM
| ID: wpr-869293
ABSTRACT
Antiviral therapy is important for COVID-19. Currently, the anti-2019-nCoV drugs in clinical trials include broad-spectrum antiviral drugs (alpha interferon and ribavirin), hemagglutinin inhibitors (arbidol), human immunodeficiency virus protease inhibitors (lopinavir/ritonavir and darunavir/cobicistat), nucleoside analogues (favipiravir and remdesivir) and antimalarial drug (chloroquine); while liver damage may occur in some patients with the medication. This article reviews the research on liver damage associated with anti-2019-nCoV drugs, aiming at promoting the safe and effective antiviral therapy for COVID-19 patients.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Chinese Journal of Clinical Infectious Diseases
Año:
2020
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS